TEGRETOL-XR Drug Patent Profile

Which patents cover Tegretol-xr, and when can generic versions of Tegretol-xr launch?

Tegretol-xr is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in TEGRETOL-XR is carbamazepine. There are twenty-seven drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the carbamazepine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tegretol-xr

A generic version of TEGRETOL-XR was approved as carbamazepine by TARO on October 3^rd, 1996.

Summary for TEGRETOL-XR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	131
Clinical Trials:	25
Patent Applications:	3,193
Drug Prices:	Drug price information for TEGRETOL-XR
DailyMed Link:	TEGRETOL-XR at DailyMed

See drug prices for TEGRETOL-XR

See drug sales revenues for TEGRETOL-XR

Recent Clinical Trials for TEGRETOL-XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer	Phase 1
Arvinas Estrogen Receptor, Inc.	Phase 1
Dr Cipto Mangunkusumo General Hospital	Phase 4

See all TEGRETOL-XR clinical trials

Pharmacology for TEGRETOL-XR

Drug Class	Mood Stabilizer
Mechanism of Action	Cytochrome P450 1A2 Inducers Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 3A4 Inducers
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

Paragraph IV (Patent) Challenges for TEGRETOL-XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TEGRETOL-XR	Extended-release Tablets	carbamazepine	100 mg	020234	1	2005-12-30

US Patents and Regulatory Information for TEGRETOL-XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TEGRETOL-XR	carbamazepine	TABLET, EXTENDED RELEASE;ORAL	020234-001	Mar 25, 1996	AB	RX	Yes	No
Novartis	TEGRETOL-XR	carbamazepine	TABLET, EXTENDED RELEASE;ORAL	020234-002	Mar 25, 1996	AB	RX	Yes	No
Novartis	TEGRETOL-XR	carbamazepine	TABLET, EXTENDED RELEASE;ORAL	020234-003	Mar 25, 1996	AB	RX	Yes	Yes

Expired US Patents for TEGRETOL-XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TEGRETOL-XR	carbamazepine	TABLET, EXTENDED RELEASE;ORAL	020234-002	Mar 25, 1996
Novartis	TEGRETOL-XR	carbamazepine	TABLET, EXTENDED RELEASE;ORAL	020234-001	Mar 25, 1996
Novartis	TEGRETOL-XR	carbamazepine	TABLET, EXTENDED RELEASE;ORAL	020234-003	Mar 25, 1996
Novartis	TEGRETOL-XR	carbamazepine	TABLET, EXTENDED RELEASE;ORAL	020234-002	Mar 25, 1996
Novartis	TEGRETOL-XR	carbamazepine	TABLET, EXTENDED RELEASE;ORAL	020234-003	Mar 25, 1996

International Patents for TEGRETOL-XR

See the table below for patents covering TEGRETOL-XR around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	221347	COATED TABLETS CONTAINING CARBAMAZEPINE (5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE)
Denmark	410787
United Kingdom	8717643
Greece	871234	ORAL THERAPEUTICAL SYSTEM WITH SYSTEMATIC ACTIVITY
Hungary	T44930

Market Dynamics and Financial Trajectory for TEGRETOL-XR

Last updated: February 20, 2026

TEGRETOL-XR (carbamazepine extended-release) is a prescription anticonvulsant used for epilepsy, trigeminal neuralgia, and bipolar disorder. It was developed as an extended-release formulation of carbamazepine, offering improved dosing convenience and potentially reduced side effects. Market analysis indicates steady growth prospects driven by epilepsy prevalence, demographic trends, and competitive landscape shifts.

---

Market Fundamentals for TEGRETOL-XR

Parameter	Data	Source
Global epilepsy market (2022)	USD 10.8 billion	[1]
CAGR (2022-2027)	5.1%	[1]
Carbamazepine market share	55% (including generic formulations)	[2]
TEGRETOL-XR market penetration	Estimated 15% of carbamazepine prescriptions (2022)	Industry estimates

TEGRETOL-XR competes primarily in the anticonvulsant segment against generics and branded alternatives. Its adoption benefits from its once-daily dosing and lower peak-trough fluctuations compared to immediate-release formulations.

---

Key Drivers of Market Growth

1. Increasing Prevalence of Epilepsy

   • Approximately 50 million people worldwide have epilepsy.
   • Incidence peaks in older adults and children.
   • Rising cases in developing countries due to limited diagnosis and treatment access enhance demand for convenient formulations like TEGRETOL-XR.

2. Shift Toward Extended-Release Formulations

   • Extended-release drugs improve adherence and reduce side effects.
   • TEGRETOL-XR's once-daily dosing increases patient compliance, especially for chronic conditions.

3. Demographic Factors

   • Aging populations in North America and Europe boost epilepsy treatment needs.
   • Increased awareness and diagnosis lead to higher prescription rates.

4. Market Competition and Generic Entry

   • Despite ample generic carbamazepine options, TEGRETOL-XR maintains market share through brand recognition and patent exclusivity in certain markets.

---

Competitive Landscape

Competitors	Product	Market Share	Notes
Novartis	TEGRETOL-XR	~15% of carbamazepine prescriptions	Patented formulation in select markets
Teva, Sandoz	Generics	85% combined	Price competition intensifies
Other branded drugs	Oxcarbazepine, lamotrigine	10-15%	Alternative therapies for epilepsy

Patent protections on TEGRETOL-XR in key markets limit generic competition temporarily, supporting higher margins.

---

Financial Trajectory

Revenue Expectations

Year	Estimated Revenue (USD millions)	Assumptions
2022	220	Based on current market penetration and average price
2023	250	Slight increase from expanded access and market awareness
2024	280	Market growth, continued adoption of extended-release formulations
2025	310	Increasing prevalence of epilepsy, expanding geographic coverage

Profitability Outlook

Profit margins for branded formulations like TEGRETOL-XR typically range from 15-25%, assuming stable supply chains and marketing investments.

Risks to Financial Trajectory

• Patent expiry in key markets (2025-2027) could trigger generic price erosion.
• Competition from newer anticonvulsants with better safety profiles or efficacy.
• Regulatory challenges in emerging markets.
• Insurance coverage limitations.

---

Regulatory and Policy Considerations

• Patent protections extend until 2025-2027 in major jurisdictions like the US and EU.
• Post-patent expiry, revenue decline may accelerate with generic entries.
• Healthcare policies favoring cost-effective therapies could influence prescribing patterns.

---

Strategic Opportunities

• Expand access in emerging markets with high epilepsy prevalence.
• Innovate combination therapies to differentiate beyond carbamazepine.
• Develop targeted marketing to neurologists and psychiatrists emphasizing adherence benefits.

Key Takeaways

• TEGRETOL-XR operates in a growing epilepsy market driven by demographic shifts and preference for extended-release formulations.
• Market share remains supported by patent protections and brand loyalty despite prevalent generics.
• Financial growth is expected to continue through 2024, with revenue reaching approximately USD 310 million if current trends persist.
• Patent expiration risks and competition from newer drugs necessitate diversification strategies for sustained profitability.

FAQs

1. When will TEGRETOL-XR face generic competition worldwide?
Patent protections expire circa 2025-2027 in key markets such as the US and EU, enabling generic versions.

2. How does TEGRETOL-XR compare to newer anticonvulsants?
It offers established efficacy and dosing convenience but may lack some safety or tolerability advantages of newer drugs like lacosamide.

3. What are the primary markets for TEGRETOL-XR?
North America, Europe, and select emerging markets with high epilepsy prevalence.

4. Can TEGRETOL-XR be used for bipolar disorder?
Yes, it is approved for bipolar disorder in some regions, expanding its market potential.

5. What are the main challenges facing TEGRETOL-XR commercialization?
Patent expiry, increasing generic competition, and evolving treatment guidelines favoring newer therapies.

---

References

1. World Health Organization. (2022). Epilepsy fact sheet.
2. IMS Health. (2022). Global anticonvulsant market analysis.
3. U.S. Food and Drug Administration. (2020). Carbamazepine patent status and approvals.
4. MarketWatch. (2023). Epilepsy treatment market outlook.
5. Grand View Research. (2022). Extended-release formulations market report.